In the context of CD44-targeted antibody treatment, Arabi et al. [206] compared the antitumour activity of Doxil and monoclonal antibody (mAb)-modified Doxil against CD44, showing a significant improvement in cellular uptake of CD44-targeted, (mAb)-modified Doxil in CD44+ murine colon carcinoma cells compared to Doxil. This evidence concerns the gene CD44 and colon carcinoma.